Jessica Neisen

BioPharmaceuticals R&D, AstraZeneca
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel disease.

Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel disease.

Journal: Pain reports

Published: January 09, 2026

Identification of novel molecular drivers, prognostic and diagnostic biomarkers for Inflammatory Bowel Disease (IBD): protocol for the Nottingham/AstraZeneca prospective IBD observational cohort study.

Identification of novel molecular drivers, prognostic and diagnostic biomarkers for Inflammatory Bowel Disease (IBD): protocol for the Nottingham/AstraZeneca prospective IBD observational cohort study.

Journal: BMJ open

Published: November 24, 2025

Plasma interleukin-22 concentration and disease activity in inflammatory bowel disease.

Plasma interleukin-22 concentration and disease activity in inflammatory bowel disease.

Journal: Scientific reports

Published: November 12, 2024

Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease.

Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease.

Journal: BMC gastroenterology

Published: May 17, 2023

Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies.

Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies.

Journal: Frontiers in pharmacology

Published: January 15, 2022

Correction to: Mathematical Modelling of Alternative Pathway of Complement System.

Correction to: Mathematical Modelling of Alternative Pathway of Complement System.

Journal: Bulletin of mathematical biology

Published: December 19, 2021

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).

Journal: The European respiratory journal

Published: July 02, 2021

Mathematical Modelling of Alternative Pathway of Complement System.

Mathematical Modelling of Alternative Pathway of Complement System.

Journal: Bulletin of mathematical biology

Published: June 07, 2019

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

Journal: Oncotarget

Published: July 22, 2015

Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.

Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.

Journal: Oncotarget

Published: June 28, 2014

Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function.

Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function.

Journal: Stem cells (Dayton, Ohio)

Published: August 21, 2012

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

Journal: European urology

Published: June 14, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026